pidilizumab
muromonab
brolucizumab
cergutuzumab
tislelizumab
double-vaxxed
abagovomab
oleclumab
cross-reactivity
elsilimomab
autocentromere
antinucleosome
-toxa-
naptumomab estafenatox
anti-nuclear factor
conatumumab
serospecific
teneliximab
fontolizumab
otelixizumab
drozitumab
polyvalent
fluorescein isothiocyanate
immunomodulant
heteroclitic
immunosorbing
fluorescein isocyanate
cedelizumab
zanolimumab
mepolizumab
sarilumab
ozogamicin
precipitin
antihaemolysin
antitoxin
antimonoclonal
talizumab
tocilizumab
immunoprobe
patritumab
polyantibody
dinutuximab
zenocutuzumab
vanucizumab
sasanlimab
sintilimab
retifanlimab
solitomab
toripalimab
pozelimab